Bleeding Prediction in Thrombocytopenia

August 26, 2019 updated by: Pernille Just Vinholt

Bleeding Prediction in Thrombocytopenia Using Platelet Indices, Platelet Aggregometry and a Standardized Bleeding Questionnaire

The purpose of the study is to investigate whether platelet indices from automated haematology equipment, whole blood impedance aggregometry and a standardized bleeding questionnaire predict bleeding in admitted patients with thrombocytopenia of various causes.

Study Overview

Status

Completed

Conditions

Detailed Description

Thrombocytopenia is a risk factor for bleeding, but studies concerning markers for stratification of bleeding risk among thrombocytopenic patients are lacking. This prospective observational cohort study investigates risk factor for bleeding in admitted patients with thrombocytopenia of various causes.

Study Type

Observational

Enrollment (Actual)

280

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Admitted patients with thrombocytopenia of any cause

Description

Inclusion Criteria:

  • Admitted patients with thrombocytopenia
  • Age ≥18 years
  • Platelet count below 80 x109/L

Exclusion Criteria:

  • Platelet transfusion within the previous 14 days,
  • surgery or trauma within the previous 7 days
  • Unable to give informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean platelet volume
Time Frame: 30 days
Mean platelet volume (femtolitre (fL))
30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Platelet count
Time Frame: 30 days
Platelet count ( x10'9/L)
30 days
immature platelet fraction
Time Frame: 30 days
immature platelet fraction (%)
30 days
Bleeding questionnaire
Time Frame: 30 days
Bleeding score based on the condensed MCMDM-1 VWD bleeding questionnaire
30 days
Platelet aggregation
Time Frame: 30 days
Platelet aggregation by Multiplate Analyzer (aggregation units* min)
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pernille J Vinholt, MD, Odense University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2013

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

November 24, 2014

First Submitted That Met QC Criteria

December 2, 2014

First Posted (Estimate)

December 3, 2014

Study Record Updates

Last Update Posted (Actual)

August 28, 2019

Last Update Submitted That Met QC Criteria

August 26, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thrombocytopenia

3
Subscribe